

ASX Announcement

Medibio Limited – 10 May 2017



Medibio Signs Strategic Joint Development Agreement with Mayo Clinic

Sydney, Australia – 10 May 2017: Medibio Limited (MEB or the Company) is pleased to announce today that it has entered into a three-year joint development agreement with Mayo Clinic to advance the expansion of technology that will provide for objective, data-driven assessment and management of mental illness.

Medibio's proprietary analytic platform utilizes a patented panel of circadian, sleep and autonomic system biomarkers to objectively quantify and characterize mental illness. By utilizing objective biomarkers, it can help guide healthcare providers in the diagnosis of psychiatric conditions in patients.

"We at Medibio welcome the opportunity to work with Mayo Clinic, which is known universally as a leader in healthcare advances," said Medibio CEO and Managing Director, Jack Cosentino. ***"It is our goal to uncover new solutions to increase the quality of life for patients."***

"We believe that Mayo Clinic provides precisely the clinical expertise Medibio needs to validate use of our technology as a decision support tool in the detection and diagnosis of depression and other mental health illnesses," said Dr. Franklyn Prendergast, member of the Medibio Board of Directors.

Mental health represents the largest clinical problem today with an estimated 350M people world-wide suffering from depression and is the leading cause of disability in the US. Given the subjective nature of the clinical assessments, less than 10% of patients receive optimal therapy following initial assessments. Under the joint agreement, Mayo Clinic and Medibio will jointly develop new product solutions to assist physicians in quantitatively addressing psychiatric conditions while also improving the quality, outcomes and costs associated with patient care.

– ENDS –

Further Information:		Website: www.medibio.com.au
Medibio Shareholder Enquiries to: Jack Cosentino CEO and Managing Director Medibio Limited jack.cosentino@medibio.com.au T: + 1 612 314 7201	Medibio Media Enquiries to: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0)412 036 231	

About Medibio Limited

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms delivering a quantifiable measure to assist in clinical diagnosis. Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market. Located in Melbourne (Vic) Medibio is listed on the Australian Securities Exchange Ltd.

For personal use only